Jefferies Financial Group Inc. Invests $9.34 Million in Celcuity, Inc. $CELC

Jefferies Financial Group Inc. purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 89,234 shares of the company’s stock, valued at approximately $9,336,000. Jefferies Financial Group Inc. owned about 0.18% of Celcuity as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its stake in Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after purchasing an additional 86 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock worth $99,000 after purchasing an additional 124 shares in the last quarter. US Bancorp DE raised its stake in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the last quarter. Intech Investment Management LLC raised its stake in shares of Celcuity by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares during the last quarter. Finally, Aristides Capital LLC lifted its holdings in shares of Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after purchasing an additional 303 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Down 1.9%

CELC opened at $93.24 on Friday. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 1-year low of $44.42 and a 1-year high of $151.02. The company has a market capitalization of $4.56 billion, a PE ratio of -21.68 and a beta of 0.20. The firm’s 50 day simple moving average is $94.63 and its two-hundred day simple moving average is $107.28.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, equities analysts forecast that Celcuity, Inc. will post -4.75 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on CELC shares. Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research report on Thursday, May 28th. Craig Hallum reissued a “buy” rating and issued a $178.00 target price on shares of Celcuity in a research report on Wednesday, July 15th. Citigroup restated a “market outperform” rating on shares of Celcuity in a research note on Monday, August 17th. Wall Street Zen downgraded shares of Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Wells Fargo & Company reduced their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.